Trials soon ready
Clinical trials expected to report results within the next 12 months, ranked by potential. Each trial shows its estimated finish date — explained in plain language.
Showing the top 50 of 85 trials in this window.
-
Can engineered immune cells outsmart Hard-to-Treat blood cancers?
⭐️ CURE ⭐️ OngoingThe purpose of this study is to evaluate the safety and preliminary activity of ARC-T cells and SPRX002 in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
Results expected Oct 2026 (estimated)
Phase: PHASE1 • Sponsor: Arcellx, Inc. • Aim: ⭐️ CURE ⭐️
Last updated Aug 13, 2026 00:00 UTC
Gilead Sciences, Inc. · GILD NASDAQ Trade on eToro (ad)Reward if it works Very highAiming at a cure or vaccine; success would transform the company.
Risk to the company ModerateA small company — one failure carries real weight.
-
Could a Virus-Like particle vaccine outsmart polio?
⭐️ VACCINE ⭐️ OngoingThis is a phase I/II randomized, double-blind, and positive-controlled study. Participants in the phase I toddler group will receive 1 dose of either high dose VLP-Polio (Dose H) or control vaccine in a ratio of 3:1. The phase I infant cohort will have 4 arms randomly assigned to…
Results expected Oct 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: CanSino Biologics Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 08, 2026 00:03 UTC
CanSino Biologics Inc. · 6185 HKEXReward if it works Very highAiming at a cure or vaccine; success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
Major RSV vaccine trial for seniors nears completion
⭐️ VACCINE ⭐️ OngoingEfficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults: * At a dose of 120µg. * In adults 60 years of age and older. * Th…
Results expected Jan 2027 (estimated)
Phase: PHASE3 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:00 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Reward if it works Very highA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Can a single eye injection restore sight in genetic blindness?
⭐️ CURE ⭐️ OngoingThis is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 in patients with retinitis pigmentosa associated with NR2E3 and RHO mutations and in patients with LCA due to mutation(s) in CEP290 gene (OCU400-101). To document prospective eye pathology in the above subjects…
Results expected Mar 2027 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: Ocugen • Aim: ⭐️ CURE ⭐️
Last updated Aug 02, 2026 00:00 UTC
Ocugen · OCGN NASDAQ Trade on eToro (ad)Reward if it works Very highAiming at a cure or vaccine; success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
New mRNA vaccine aims to stop the stomach flu
⭐️ VACCINE ⭐️ OngoingThe primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prevent protocol-defined moderate or severe norovirus acute gastroenteritis (AGE) associated with vaccine matched genotypes.
Results expected Feb 2027 (estimated)
Phase: PHASE3 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:33 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Reward if it works Very highA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New COVID-19 vaccine candidate tested alone or as a booster with mRNA shots
⭐️ VACCINE ⭐️ Recruiting nowThe main purposes of this research study are to measure the safety (whether it causes any side effects), tolerability (if it does cause any side effects, how well your body is able to handle them), and reactions, both local at the injection site and systemic, that may occur in th…
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: Invivyd, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 14:00 UTC
InVivyd · IVVD NASDAQ Trade on eToro (ad) -
New RSV vaccine candidate aims to shield older adults from severe lung infections
⭐️ VACCINE ⭐️ Recruiting nowThis Phase I/II study is to characterize the safety and immunogenicity of 2 dose levels of AZD6489, an investigational RSV recombinant prefusion F protein VLP vaccine.
Results expected Oct 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 23, 2026 00:00 UTC
AstraZeneca · AZN NASDAQ Trade on eToro (ad)Reward if it works HighAiming at a cure or vaccine; success would still be major news.
Risk to the company Very lowA large company running many trials — it absorbs a failure here.
-
Pfizer gives lyme vaccine a fifth dose — will it boost protection?
⭐️ VACCINE ⭐️ Recruiting nowThe purpose of this study is to learn about the safety effects of the Lyme disease vaccine (called VLA15), and its ability to protect people from Lyme disease after a 5th dose of the vaccine. This study is seeking participants who: * are generally healthy and 7 years of age and…
Results expected Dec 2026 (estimated)
Phase: PHASE3 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:29 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Reward if it works Very highA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New vaccine aims to shield sickle cell kids from deadly infections
⭐️ VACCINE ⭐️ Recruiting nowThe purpose of this study is to measure whether PCV21 vaccine (investigational pneumococcal vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 20vPCV (licensed pneumococcal vaccine) when given as a single dose…
Results expected Jan 2027 (estimated)
Phase: PHASE3 • Sponsor: Sanofi • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:08 UTC
Sanofi · SNY NASDAQ Trade on eToro (ad)Reward if it works Very highA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New mRNA shot targets bird flu: 4,000 volunteers needed
⭐️ VACCINE ⭐️ OngoingThe purpose of this study is to evaluate humoral immunogenicity after 2 doses of mRNA-1018-H5, and to evaluate the safety and reactogenicity of mRNA-1018-H5 in adults ≥18 years of age.
Results expected Jan 2027 (estimated)
Phase: PHASE3 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 13, 2026 00:00 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Reward if it works Very highA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New meningitis vaccine trial aims to shield babies from deadly infection
⭐️ VACCINE ⭐️ Recruiting nowThe goal of this clinical trial is to evaluate the immunogenicity, safety, and immune persistence of the primary series of an investigational group ACYW135 meningococcal conjugate vaccine, as well as the immunogenicity and safety of a booster dose administered at 12 months of age…
Results expected Apr 2027 (estimated)
Phase: PHASE3 • Sponsor: Sinovac Biotech Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 12, 2026 00:00 UTC
Sinovac Biotech Co., Ltd. · SVA NASDAQReward if it works Very highA late-stage readout — success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
New dengue vaccine trial targets older adults and those with chronic illness
⭐️ VACCINE ⭐️ Recruiting nowDengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever. Researchers have seen that dengue fever now also happens more often in elderly persons. The main aim of this study is to learn more about…
Results expected Apr 2027 (estimated)
Phase: PHASE3 • Sponsor: Takeda • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:24 UTC
Takeda · TAK NYSE Trade on eToro (ad)Reward if it works Very highA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New mRNA vaccine against mpox enters key trial in africa
⭐️ VACCINE ⭐️ Recruiting nowThis is a randomized, double-blind, placebo-controlled study which aims to assess the safety, reactogenicity, and immunogenicity after one and two doses of BNT166a or placebo in healthy participants.
Results expected Jun 2027 (estimated)
Phase: PHASE2 • Sponsor: BioNTech SE • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 13, 2026 00:00 UTC
BioNTech SE · BNTX NASDAQ Trade on eToro (ad)Reward if it works HighAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Engineered immune cells take aim at hard-to-treat blood cancers
⭐️ CURE ⭐️ Recruiting nowThis is a Phase 1 (a and b), first in human (FIH), single-arm, open-label, multicenter study to evaluate the safety, tolerability and efficacy of GCC2005 in the treatment of patients with relapsed/refractory (R/R) NK or T-cell malignancies who have received at least two prior lin…
Results expected Aug 2027 (estimated)
Phase: PHASE1 • Sponsor: GC Cell Corporation • Aim: ⭐️ CURE ⭐️
Last updated Jul 26, 2026 00:00 UTC
GC Cell Corporation · 144510 KOSDAQReward if it works HighAiming at a cure or vaccine; success would transform the company.
Risk to the company ModerateA small company — one failure carries real weight.
-
New RSV vaccine aims to shield adults from severe respiratory infection
⭐️ VACCINE ⭐️ Recruiting nowThe purpose of this phase 3 multicenter, double-blinded, placebo-controlled study in India is to learn about the safety and immunogenicity of RSVpreF in adults.
Results expected Jan 2027 (estimated)
Phase: PHASE3 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 16, 2026 00:00 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Could a vaccine stop recurrent UTIs? new trial underway
⭐️ VACCINE ⭐️ Recruiting nowThe purpose of this study is to assess safety, reactogenicity, and immune response of the candidate UTI vaccine compared to placebo in adults between and including 18-64 years of age (YOA), and to perform a preliminary evaluation of clinical efficacy in females between and includ…
Results expected May 2027 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:23 UTC
GSK · GSK NYSE Trade on eToro (ad)Reward if it works HighAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
One shot, two viruses? new mRNA vaccine targets RSV and hMPV
⭐️ VACCINE ⭐️ Not yet recruitingThe main objective of this trial is to evaluate the safety, reactogenicity, and immunogenicity of study interventions across intervention groups
Results expected Jul 2027 (estimated)
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 15, 2026 00:00 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Reward if it works ModerateAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New yellow fever vaccine trial for kids could boost global protection
⭐️ VACCINE ⭐️ Recruiting nowThe purpose of this study is to determine whether vYF (investigational vaccine) is safe and can help the body to develop antibodies (immunogenicity) compared with Stamaril vaccine and YF-VAX vaccine (both licensed vaccines) and when they are co-administered with Measles Mumps Rub…
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: Sanofi • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:29 UTC
Sanofi · SNY NASDAQ Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New RSV vaccine trial targets High-Risk adults in japan
⭐️ VACCINE ⭐️ Recruiting nowThe purpose of the study is to learn about the immune response after a RSVpreF vaccination. This study is being conducted in Japan. RSV is a common virus that can cause infections of the lungs and airways. The study is seeking participants who are: * 18 to 59 years of age * adu…
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:00 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New 24-Valent vaccine aims to shield children from more pneumonia strains
⭐️ VACCINE ⭐️ Recruiting nowA Phase 2 clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in the pediatric population aged 2 months (minimum 42 days) to 5 years. The objective of the study is to evaluate the safety and immunogenici…
Results expected Sep 2026 (estimated)
Phase: PHASE2 • Sponsor: Sinovac Life Sciences Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:06 UTC
Sinovac Biotech Ltd. · SVA NASDAQReward if it works ModerateAiming at a cure or vaccine; success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
MRNA technology takes on the stomach flu: moderna launches norovirus vaccine trial
⭐️ VACCINE ⭐️ OngoingThe purpose of the Part A Phase 1 of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1403 and mRNA-1405 in healthy adult participants 18 to 49 years of age and 60 to 80 years of age. The purpose of Part B Phase 2 and Part C Phase 2 is to evaluate …
Results expected Sep 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:03 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Reward if it works ModerateAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
RSV booster study aims to keep seniors safe for five seasons
⭐️ VACCINE ⭐️ OngoingThe purpose of this study is: * To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose, * To evaluate the long-term immune persistence and safety up to 5 consecutive RSV seasons (approximately 60 months) of a single dose of RSVPreF3 OA vac…
Results expected Sep 2026 (estimated)
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 31, 2026 00:00 UTC
GSK · GSK NYSE Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New vaccine aims to protect african children from deadly salmonella
⭐️ VACCINE ⭐️ OngoingThe purpose of this study is to evaluate the safety, reactogenicity, and immune response of the GlaxoSmithKline (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-generalized modules for membrane antigens (iNTS-GMMA) candidate vaccine against S. Ty…
Results expected Sep 2026 (estimated)
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:35 UTC
GSK · GSK NYSE Trade on eToro (ad)Reward if it works ModerateAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Could a Freeze-Dried vaccine shield all ages from hib?
⭐️ VACCINE ⭐️ OngoingThis trial is a randomized, partially blinded, positively controlled phase I clinical study. A total of 160 persons aged 18-59 years, 1-5 years, 6-11 months and 2 months (60-89 days) will be recruited into the trial, and the enrollment will be done according to the progression of…
Results expected Oct 2026 (estimated)
Phase: PHASE1 • Sponsor: CanSino Biologics Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 08, 2026 00:03 UTC
CanSino Biologics Inc. · 6185 HKEXReward if it works ModerateAiming at a cure or vaccine; success would transform the company.
Risk to the company ModerateA small company — one failure carries real weight.
-
Pregnancy vaccine shields newborns from RSV: Real-World data reveals impact
⭐️ VACCINE ⭐️ OngoingThis study will be conducted in collaboration with a research network of independent hospital sites to evaluate the vaccine effectiveness (VE) and impact of ABRYSVO vaccination during pregnancy in a real-world population over multiple seasons, which began in 2024 across Argentina…
Results expected Oct 2026 (estimated)
Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:34 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Reward if it works ModerateAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
BioNTech launches first human test of mRNA herpes vaccine
⭐️ VACCINE ⭐️ OngoingThis exploratory trial will have three parts. Part A is a dose escalation part, Part B is an expanded safety and dose evaluation part, and Part C is a safety and immunogenicity evaluation part in individuals with recurrent HSV-2 genital herpes. Part A will focus on the safety ev…
Results expected Oct 2026 (estimated)
Phase: PHASE1 • Sponsor: BioNTech SE • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:55 UTC
BioNTech SE · BNTX NASDAQ Trade on eToro (ad)Reward if it works ModerateAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Could this mRNA vaccine stop the virus behind mono and certain cancers?
⭐️ VACCINE ⭐️ OngoingThe main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults, the main objective of Part B is to evaluate the safety and reactogenicity of mRNA-1189 in 12- to \<18-year-old healthy EBV-seronegative adole…
Results expected Oct 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:29 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Reward if it works ModerateAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Moderna launches first human test of mRNA vaccine against Epstein-Barr virus
⭐️ VACCINE ⭐️ OngoingThe purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy participants.
Results expected Oct 2026 (estimated)
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 13, 2026 00:00 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Reward if it works ModerateAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New meningitis vaccine for kids shows promise in large trial
⭐️ VACCINE ⭐️ OngoingThe goal of this clinical trial is to evaluate the immunogenicity and safety of an investigational group ACYW135 meningococcal conjugate vaccine in healthy children aged 2 to 6 years. The main questions it aims to answer are: Is the immune response induced by the investigationa…
Results expected Nov 2026 (estimated)
Phase: PHASE3 • Sponsor: Sinovac Biotech Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 12, 2026 00:00 UTC
Sinovac Biotech Co., Ltd. · SVA NASDAQReward if it works HighA late-stage readout — success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
New novavax JN.1 vaccine trial aims to protect adults 50-64 from COVID
⭐️ VACCINE ⭐️ OngoingThis is a Phase 4, post-market US study, evaluating the efficacy and safety of a single dose of the NVX-CoV2705 Omicron JN.1 COVID-19 vaccine. Approximately 6,500 healthy adults aged 50 to under 65 will be randomized to receive either the vaccine or a placebo, with follow-up for …
Results expected Nov 2026 (estimated)
Phase: PHASE4 • Sponsor: Novavax • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:30 UTC
Novavax · NVAX NASDAQ Trade on eToro (ad)Reward if it works ModerateAiming at a cure or vaccine; success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
New 24-Strain pneumonia vaccine enters human trials
⭐️ VACCINE ⭐️ Recruiting nowThis clinical trial consists of Phase I and Phase II. The objective is to evaluate the safety and immunogenicity of the 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) in individuals aged 2 months (minimum 6 weeks) and older.
Results expected Nov 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: CanSino Biologics Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 07, 2026 00:00 UTC
CanSino Biologics Inc. · 6185 HKEXReward if it works ModerateAiming at a cure or vaccine; success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
Mpox vaccine gets a production upgrade: new cell recipe under trial
⭐️ VACCINE ⭐️ OngoingRandomized, double-blind, phase 2b trial to assess comparability in immunogenicity, safety, and reactogenicity of MVA-BN vaccine manufactured in primary chicken embryo fibroblast (CEF) cells and the CCX.E10 quail cell line in adults
Results expected Nov 2026 (estimated)
Phase: PHASE2 • Sponsor: Bavarian Nordic • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:05 UTC
Bavarian Nordic · BVNRY OTCReward if it works ModerateAiming at a cure or vaccine; success would still be major news.
Risk to the company ModerateA mid-sized company with other programmes alongside this one.
-
New mRNA flu vaccine trial aims to stop future pandemics
⭐️ VACCINE ⭐️ OngoingThe purpose of this phase 1/2 study is to investigate the safety and immunogenicity of different doses (high, medium and low) of a second generation structurally designed (SD2) H5 messenger ribonucleic acid (mRNA) vaccine against pandemic H5 influenza virus (pandemic flu H5 hemag…
Results expected Dec 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:12 UTC
Sanofi · SNY NASDAQ Trade on eToro (ad)Reward if it works ModerateAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New vaccine aims to protect kids from pneumonia – study underway
⭐️ VACCINE ⭐️ OngoingThe purpose of this study is to evaluate the safety and immunogenicity of PCV21 versus 20vPCV ( 20-valent pneumococcal conjugate vaccine, Prevnar 20) for catch-up vaccination in infants (7 to 11 MoA-Months of age), toddlers (12 to 23 MoA), and children/adolescents (2 to 5 YoA and…
Results expected Dec 2026 (estimated)
Phase: PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:53 UTC
Sanofi S.A. · SNY NASDAQ Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New vaccine aims to shield against multiple coronavirus types
⭐️ VACCINE ⭐️ Recruiting nowThe purpose of this research study is to evaluate the safety of and the body's immune response to single and multiple vaccinations in healthy men and women. We want to find out what effects GBP511 has on you and your health. We are doing this study to find out: If the study drug…
Results expected Dec 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: SK Bioscience Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:33 UTC
SK Bioscience Co., Ltd. · 302440 KRXReward if it works ModerateAiming at a cure or vaccine; success would still be major news.
Risk to the company ModerateA mid-sized company with other programmes alongside this one.
-
New chickenpox shot shows promise in toddler trial
⭐️ VACCINE ⭐️ Recruiting nowThe purpose of this study is to evaluate the immune response and safety of GSKs investigational varicella vaccine (VNS Vaccine) compared to an already approved varicella vaccine, Varivax (VV), when administered as second dose to healthy children. 3 months after first dose at 12 t…
Results expected Dec 2026 (estimated)
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:00 UTC
GSK · GSK NYSE Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New mRNA vaccines aim to outsmart evolving COVID variants
⭐️ VACCINE ⭐️ Recruiting nowThe purpose of this study is to investigate the immunogenicity and safety of mRNA COVID-19 variant-containing vaccine formulations against the vaccine-matched variants and newly emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Results expected Dec 2026 (estimated)
Phase: PHASE4 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:01 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Reward if it works ModerateAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New vaccine aims to better protect blood cancer patients from COVID-19
⭐️ VACCINE ⭐️ OngoingThis phase 2 trial studies the immune response to GEO-CM04S1 (previously designated as COH04S1) compared to standard of care (SOC) mRNA SARS-COV-2 vaccine in patients with blood cancer who have received stem cell transplant or cellular therapy. GEO-CM04S1 belongs to a category c…
Results expected Dec 2026 (estimated)
Phase: PHASE2 • Sponsor: GeoVax, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:04 UTC
GeoVax, Inc. · GOVX NASDAQ Trade on eToro (ad)Reward if it works HighAiming at a cure or vaccine; success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
New meningitis vaccine for toddlers shows promise in major trial
⭐️ VACCINE ⭐️ Recruiting nowThe goal of this clinical trial is to evaluate the immunogenicity and safety of an investigational group ACYW135 Meningococcal conjugate vaccine in healthy children aged 12 to 23 months. The main questions it aims to answer are: Is the immune response induced by the investigati…
Results expected Jan 2027 (estimated)
Phase: PHASE3 • Sponsor: Sinovac Biotech Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 12, 2026 00:00 UTC
Sinovac Biotech Co., Ltd. · SVA NASDAQReward if it works HighA late-stage readout — success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
New RSV vaccine trial offers hope for transplant patients
⭐️ VACCINE ⭐️ OngoingThis study evaluates persistence of the immune response of the adjuvanted RSV vaccine and the safety and immunogenicity following revaccination in adults 18 years of age and above who received lung or kidney transplant.
Results expected Jan 2027 (estimated)
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 01, 2026 00:00 UTC
GSK · GSK NYSE Trade on eToro (ad)Reward if it works ModerateAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Double defense: new mRNA vaccine targets two lung viruses in seniors
⭐️ VACCINE ⭐️ OngoingThe aim of this study is to evaluate the safety and immunogenicity of a human metapneumovirus (hMPV) / respiratory syncytial virus (RSV) mRNA vaccine candidate encapsulated in a lipid nanoparticle (LNP) based formulation (hereafter referred to as hMPV/RSV vaccine) for the prevent…
Results expected Jan 2027 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:03 UTC
Sanofi S.A. · SNY NASDAQ Trade on eToro (ad)Reward if it works ModerateAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New vaccine aims to stop rare but deadly brain infections from mosquitoes
⭐️ VACCINE ⭐️ OngoingThis phase 2 clinical trial will investigate an optimal dose, dosing regimen, and evaluate reactogenicity, safety and immunogenicity in healthy adult participants of the recombinant, multivalent MVA-BN-WEV vaccine. MVA-BN-WEV is intended for active immunization for prevention of …
Results expected Feb 2027 (estimated)
Phase: PHASE2 • Sponsor: Bavarian Nordic • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:52 UTC
Bavarian Nordic · BVNRY OTCReward if it works ModerateAiming at a cure or vaccine; success would still be major news.
Risk to the company ModerateA mid-sized company with other programmes alongside this one.
-
Could a new vaccine beat chickenpox? large trial underway
⭐️ VACCINE ⭐️ Not yet recruitingThe goal of this study is to evaluate the safety and immunogenicity of an investigational varicella vaccine in children. Researchers will compare the investigational vaccine, NBP608, with licensed varicella vaccines. The study includes children aged 12 months to 12 years. Approx…
Results expected Feb 2027 (estimated)
Phase: PHASE3 • Sponsor: SK Bioscience Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 14:00 UTC
SK Bioscience Co., Ltd. · 302440 KRXReward if it works HighA late-stage readout — success would still be major news.
Risk to the company ModerateA mid-sized company with other programmes alongside this one.
-
New vaccine aims to shield infants from deadly pneumonia
⭐️ VACCINE ⭐️ OngoingThis is a Phase 3 randomized, observation-blinded, active-controlled, parallel-group clinical trial designed to evaluate the immunogenicity, safety, and functional antibody response of the experimental vaccine versus the control vaccine in healthy Thailand infants vaccinated at a…
Results expected Feb 2027 (estimated)
Phase: PHASE3 • Sponsor: CanSino Biologics Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 07, 2026 00:00 UTC
CanSino Biologics Inc. · 6185 HKEXReward if it works HighA late-stage readout — success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
New pneumonia vaccine VAX-31 aims to boost protection in older adults
⭐️ VACCINE ⭐️ OngoingThe study will evaluate the safety, tolerability, and immunogenicity of VAX-31 in adults ≥50 years of age.
Results expected Mar 2027 (estimated)
Phase: PHASE3 • Sponsor: Vaxcyte, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 02, 2026 00:00 UTC
Vaxcyte, Inc. · PCVX NASDAQ Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company ModerateA mid-sized company with other programmes alongside this one.
-
New mRNA vaccine trial aims to stop genital herpes
⭐️ VACCINE ⭐️ ENROLLING_BY_INVITATIONA Preliminary Evaluation of the Safety and Immunogenicity Post-Vaccination with Different Doses of an mRNA Vaccine against Herpes Simplex Virus Type 2 (HSV-2) in Populations with Different Serostatus
Results expected Mar 2027 (estimated)
Phase: PHASE1 • Sponsor: Changchun BCHT Biotechnology Co. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:09 UTC
Changchun BCHT Biotechnology Co. · 688276 SSEReward if it works ModerateAiming at a cure or vaccine; success would transform the company.
Risk to the company ModerateA small company — one failure carries real weight.
-
New mRNA vaccine aims to shield transplant patients from dangerous virus
⭐️ VACCINE ⭐️ OngoingThe main purpose of the study is to evaluate the efficacy and safety of mRNA-1647 compared to placebo to prevent first clinically significant cytomegalovirus infection (CS-CMVi) in the period following cessation of CMV prophylactic treatment (for example, letermovir) on Day 100 p…
Results expected Mar 2027 (estimated)
Phase: PHASE2 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 12, 2026 00:00 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Reward if it works ModerateAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
One shot to rule them all? new combo meningitis vaccine tested in teens
⭐️ VACCINE ⭐️ OngoingThe purpose of this study is to assess the safety, tolerability, and immunogenicity of the combined meningococcal groups A, B, C, W and Y (MenABCWY) vaccine (GSK3536819A) intended to protect against invasive meningococcal disease (IMD) caused by all 5 meningococcal serogroups.
Results expected Mar 2027 (estimated)
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:06 UTC
GSK · GSK NYSE Trade on eToro (ad)Reward if it works ModerateAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New mRNA shingles vaccine enters phase 2 trial – could it be a game changer?
⭐️ VACCINE ⭐️ Not yet recruitingHerpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging. Vaccination plays a key role in reducing the disease bur…
Results expected Mar 2027 (estimated)
Phase: PHASE2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:12 UTC
CSPC Pharmaceutical Group Limited · 1093 HKEXReward if it works ModerateAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New meningitis vaccine trial aims to protect babies
⭐️ VACCINE ⭐️ Recruiting nowThe goal of this clinical trial is to evaluate the immunogenicity, safety, and persistence of the immune response of a group ACYW135 meningococcal conjugate vaccine in healthy children aged 6 to 11 months. The main questions it aims to answer are: Is the immune response induced…
Results expected Apr 2027 (estimated)
Phase: PHASE3 • Sponsor: Sinovac Biotech Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 12, 2026 00:00 UTC
Sinovac Biotech Co., Ltd. · SVA NASDAQReward if it works HighA late-stage readout — success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
Not investment advice. This page lists publicly registered clinical trials and the companies running them, for information only. A trial finishing is not a result, and a result is not an approval. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to a broker we have a commercial relationship with, and we may earn a commission if you open an account. This never affects which trials are listed or how they are ranked.